» Articles » PMID: 8339260

Main Drug-metabolizing Enzyme Systems in Human Breast Tumors and Peritumoral Tissues

Overview
Journal Cancer Res
Specialty Oncology
Date 1993 Aug 1
PMID 8339260
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

In an attempt to better understand breast tumors sensitivity or resistance to anticancer drugs, the main drug-metabolizing enzyme systems were evaluated in both breast tumors and their corresponding peritumoral tissues in 12 patients. The following enzymes were assayed by Western blot: cytochromes P-450 (1A1/A2, 2B1/B2, 2C8-10, 2E1, 3A4); glutathione S-transferases (GST-alpha, -mu, and -pi); and epoxide hydrolase. The activity of the following enzymes or cofactor were determined by spectrophotometric or fluorometric assays: GST; total glutathione; UDP-glucuronosyltransferase; beta-glucuronidase; sulfotransferase; and sulfatase. Results showed the absence of all probed cytochromes P-450 in both tumoral and peritumoral tissues. GST activity was significantly (P < 0.05) higher in tumors (mean +/- SD, 399 +/- 362 nmol/min/mg) than in corresponding peritumoral tissues (86 +/- 67). The GST isoenzymes GST-mu and GST-pi (determined by immunoblotting) were also higher in tumors than in corresponding peritumoral tissues (3- and 5-fold, respectively). Both GST-mu and GST-pi levels were significantly correlated with GST activity. GST-alpha was not detected in either tumoral or peritumoral tissues. Glutathione levels in tumors (22 +/- 23 nmol/mg protein) were not statistically different from peritumoral tissues (11 +/- 12). Epoxide hydrolase was expressed at similar levels in tumors and peritumoral tissues. The glucuronide-forming enzyme UDP-glucuronosyltransferase was 5-fold lower in tumors (0.1 +/- 0.2 nmol/h/mg) than in peritumoral tissues (0.5 +/- 1), whereas the opposite was observed for the hydrolytic enzyme beta-glucuronidase, which was 6-fold higher in tumors (736 +/- 1392 nmol/h/mg) compared to peritumoral tissues (125 +/- 75). No difference was noted between tumoral and peritumoral tissues for sulfotransferase (1 +/- 2 nmol/h/mg), but the corresponding hydrolytic enzyme (sulfatase) was 2-fold higher in tumoral tissues (14 +/- 15 nmol/h/mg) than in peritumoral tissues (6 +/- 2). In conclusion, several differences were observed between human breast tumors and peritumoral tissues for many conjugating enzymes (GST-mu, GST-pi, and UDP-glucuronosyltransferase) and hydrolytic enzymes (sulfatase and beta-glucuronidase). These noteworthy differences between tumoral and peritumoral tissues with regard to their main drug-metabolizing enzymes could play a role in the relative drug sensitivity or insensitivity of human breast cancer tissues to chemotherapeutic agents and could be potential targets for chemotherapeutic interventions.

Citing Articles

ETx-22, a Novel Nectin-4-Directed Antibody-Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4-Expressing Tumors.

Lopez M, Crompot E, Josselin E, Farina A, Rubis M, Castellano R Cancer Res Commun. 2024; 4(11):2998-3012.

PMID: 39440991 PMC: 11583010. DOI: 10.1158/2767-9764.CRC-24-0176.


Induced volatolomics of pathologies.

Djago F, Lange J, Poinot P Nat Rev Chem. 2023; 5(3):183-196.

PMID: 37117532 DOI: 10.1038/s41570-020-00248-z.


Antibody drug conjugates as targeted cancer therapy: past development, present challenges and future opportunities.

Maiti R, Patel B, Patel N, Patel M, Patel A, Dhanesha N Arch Pharm Res. 2023; 46(5):361-388.

PMID: 37071273 PMC: 11345756. DOI: 10.1007/s12272-023-01447-0.


Linkers: An Assurance for Controlled Delivery of Antibody-Drug Conjugate.

Sheyi R, de la Torre B, Albericio F Pharmaceutics. 2022; 14(2).

PMID: 35214128 PMC: 8874516. DOI: 10.3390/pharmaceutics14020396.


Sulfatase-cleavable linkers for antibody-drug conjugates.

Bargh J, Walsh S, Isidro-Llobet A, Omarjee S, Carroll J, Spring D Chem Sci. 2021; 11(9):2375-2380.

PMID: 34084399 PMC: 8157321. DOI: 10.1039/c9sc06410a.